We have observed
9 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after September 18, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA
BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME
PYRIDINE COMPOUNDS AND USES THEREOF
QUINOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS
METHODS OF TREATING ALZHEIMER'S DISEASE AND PHARMACEUTICAL COMPOSITIONS THEREOF
RADIOLABELLED PHENYLIMIDAZOLE-BASED LIGANDS
METHOD FOR RESOLUTION OF 4-((1R,3S)-6-CHLORO-3-PHENYL-INDAN-1-YL)-1,2,2-TRIMETHYL-PIPERAZINE AND 1-((1R,3S)-6-CHLORO-3-PHENYL-INDAN, 1-YL)-3,3-DIMETHYL-PIPERAZINE
IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS